Directorate Change

RNS Number : 4867T

Tissue Regenix Group PLC

06 January 2017

 

Tissue Regenix Group plc

Appointment of Group Finance Director

Leeds, 06 January 2017 - Tissue Regenix Group (AIM:TRX) ("Tissue Regenix" or "The Group") the regenerative medical devices company today announce the appointment of Paul Devlin as Group Finance Director and Company Secretary with immediate effect.

Mr Devlin brings a wealth of experience having worked on both domestic and international mergers and acquisitions, business transformations, large and small scale business start ups, joint ventures and disposals throughout the last 20 years. He joins Tissue Regenix from an interim assignment for a private equity house and prior to this, was Group Finance Director at Fletchers Bakeries Limited, which was sold to Finsbury Food Group plc in October 2014.

Antony Odell, CEO, Tissue Regenix Group commented: "We are delighted to welcome Paul as Group Finance Director. He will play a pivotal role in the strategic direction of Tissue Regenix over the coming years and the experience he brings will be invaluable to the company as we accelerate the breadth, depth and scope of our commercial activity." 

Further information:

Full name: Paul John Devlin

Age: 50

Directorships history:

-      Fletchers Bakeries Limited; Director, January 2008-June 2016

-      Nicholas and Harris Limited; Director, December 2014-March 2016

-      Oakdale Bakeries Limited, Oakdale Holdings Limited; July 2005-Feb 2007; companies placed in administration, no action or investigation by FCA or other bodies

There is no further information to be disclosed in accordance with the requirements of Schedule Two paragraph (g) of the AIM rules.

For more Information:

Tissue Regenix Group plc Caitlin Pearson                                 Corporate Communications Officer	Tel: [phone]
Jefferies International Ltd Simon Hardy / Harry Nicholas	Tel: [phone]

About Tissue Regenix

Tissue Regenix is a leading medical devices company in the field of regenerative medicine. The company's patented decellularisation ('dCELL®') technology removes DNA and other cellular material from animal and human tissue leaving an acellular tissue scaffold which is not rejected by the patient's body which can then be used to repair diseased or worn out body parts. The potential applications of this process are diverse and address many critical clinical needs such as vascular disease, heart valve replacement and knee repair.

 Tissue Regenix was formed in 2006 when it was spun-out from the University of Leeds. The company commercialises academic research conducted by our partners around the World.

 In November 2012 Tissue Regenix Group plc set up a subsidiary company in the United States - 'Tissue Regenix Wound Care Inc.', as part of its commercialisation strategy for its dCELL® technology platform.

 

END

 

 

BOAUGUAGGUPMGMA